Glaucoma is a chronic, degenerative optic neuropathy, which cause progressive damage to the optic nerve, retinal ganglion cell (RGC) death and characteristic damage to the visual field. Current glaucoma therapeutics lower intraocular pressure (IOP) but they do not repair the damaged optic nerve or reverse vision loss. So, new treatment strategies are in demand. Stem cell therapy presents a new intervention that holds great promise for reversing vision loss. There are at least 3 potential targets for stem cell therapy in glaucoma: the retinal ganglion cells , the optic nerve head, and the trabecular meshwork. Stem cells also have a neuroprotective effect in glaucoma by improving retinal ganglion cell survival. There are many obstacles in using stem cells in glaucoma as the regulation of differentiation, integration, host immune response, tumorigenesis and ethical concerns.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.